HealthDay on MSN2h
AHA: GLP-1 RA, SGLT-2i Use Can Lower Risk for MI, Recurrent Stroke in Stroke Survivors
For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor ...
Hosted on MSN3h
SGLT-2 Inhibitors Beneficial for Patients With Nephrolithiasis
TUESDAY, Nov. 12, 2024 (HealthDay News) -- For patients with nephrolithiasis, sodium-glucose cotransporter-2 (SGLT-2) ...
Business Insider6h
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA™ FDA Advisory Committee Meeting; PDUFA Goal Date December 20, ...
optometryadvisor9h
FDA Drug Approval Decisions Expected in December 2024
The Prescription Drug User Fee Act date refers to the deadline set by the FDA for reviewing a NDA or Biologics License Application.
Becker's Hospital Review10h
GLP-1, SGLT2s lower mortality risk by 74% in stroke survivors: Study
Stroke survivors who took GLP-1 or SGLT2 medications had a 74% lower risk of death, according to a preliminary study being presented at the American Heart Association's annual Scientific Sessions, set ...
Daily11h
Canagliflozin Enhances Iron Utilization and Hemoglobin Levels in Diabetic CKD Patients, CREDENCE Trial Reveals
"Canagliflozin was linked to enhanced iron utilization and elevated hemoglobin levels in adults with type 2 diabetes and ...
Endocrinology Advisor14h
GLP-1RA Drugs, SGLT2 Inhibitors Prevent Liver Disease in T2D
GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.
Knowridge17h
This weight-loss drug may reduce heart attack risk in stroke survivors
A recent study has shown that the weight-loss drug Ozempic, along with other medications in its class, may significantly ...